The calculations of (loss) earnings per share are as follows: | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended
June 30, | | Six Months Ended
June 30, | | ($ and shares in millions except per share amounts) | 2026 | | 2025 | | 2026 | | 2025 | Net (Loss) Income Attributable to Merck & Co., Inc. | $ | (1,335) | | | $ | 4,427 | | | $ | (5,575) | | | $ | 9,506 | | | Average common shares outstanding | 2,470 | | | 2,510 | | | 2,471 | | | 2,516 | | Common shares issuable (1) | — | | | 3 | | | — | | | 6 | | | Average common shares outstanding assuming dilution | 2,470 | | | 2,513 | | | 2,471 | | | 2,522 | | Basic (Loss) Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders | $ | (0.54) | | | $ | 1.76 | | | $ | (2.26) | | | $ | 3.78 | | (Loss) Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders | $ | (0.54) | | | $ | 1.76 | | | $ | (2.26) | | | $ | 3.77 | |
(1) Issuable primarily under share-based compensation plans.
|